Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis - PubMed (original) (raw)

Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis

Christopher Hewitt et al. Arch Neurol. 2010 Apr.

Abstract

Objective: To determine the frequency of and clinicopathologic phenotypes associated with FUS/TLS mutations in a large cohort of amyotrophic lateral sclerosis (ALS) cases from the north of England.

Design: Genetic screening project with neuropathologic examination of postmortem tissue in selected cases. The clinical details of selected cases are also presented.

Setting: Neurology departments of 2 university teaching hospitals in the north of England.

Participants: The 15 exons of FUS/TLS were sequenced in an initial cohort of 42 familial ALS (FALS) and 117 sporadic ALS (SALS) cases. Exons 14 and 15 were subsequently screened in a larger cohort of 431 SALS cases. Regions mutated in ALS cases were also screened in 293 controls.

Main outcome measure: Evaluation of gene-sequencing chromatographs and detailed histopathologic analysis of the central nervous system.

Results: Four heterozygous mutations, 1 of which is novel, were identified in 6 patients with ALS (4 with FALS and 2 with SALS). Two of the substitutions were not found to be present in controls, and neuropathology in these cases revealed neuronal and/or glial cytoplasmic inclusions positive for the FUS/TLS protein. One of these cases is also the first reported SALS case with an FUS/TLS mutation. The other 2 substitutions identified were also identified in control cases. Neuropathology in these cases revealed typical SALS pathology, suggesting that they are likely to represent benign polymorphisms.

Conclusions: FUS/TLS mutations represented approximately 5% of FALS cases screened. A FUS/TLS mutation was also identified in a single SALS case. Subsequent screening of this region in a larger cohort of SALS cases, however, did not reveal any additional mutations.

PubMed Disclaimer

Cited by

RNA-binding proteins with prion-like domains in ALS and FTLD-U.
Gitler AD, Shorter J. Gitler AD, et al. Prion. 2011 Jul-Sep;5(3):179-87. doi: 10.4161/pri.5.3.17230. Epub 2011 Jul 1. Prion. 2011. PMID: 21847013 Free PMC article. Review.
Protein disulphide isomerase (PDI) is protective against amyotrophic lateral sclerosis (ALS)-related mutant Fused in Sarcoma (FUS) in in vitro models.
Parakh S, Perri ER, Vidal M, Sultana J, Shadfar S, Mehta P, Konopka A, Thomas CJ, Spencer DM, Atkin JD. Parakh S, et al. Sci Rep. 2021 Sep 2;11(1):17557. doi: 10.1038/s41598-021-96181-2. Sci Rep. 2021. PMID: 34475430 Free PMC article.
ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation.
King A, Troakes C, Smith B, Nolan M, Curran O, Vance C, Shaw CE, Al-Sarraj S. King A, et al. Acta Neuropathol Commun. 2015 Oct 9;3:62. doi: 10.1186/s40478-015-0235-x. Acta Neuropathol Commun. 2015. PMID: 26452761 Free PMC article.
Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?
Donnelly CJ, Grima JC, Sattler R. Donnelly CJ, et al. Neurodegener Dis Manag. 2014;4(6):417-37. doi: 10.2217/nmt.14.36. Neurodegener Dis Manag. 2014. PMID: 25531686 Free PMC article.
Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.
Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S, Martindale J, Hartley J, Walsh T, Gelsthorpe C, Baxter L, Forster G, Fox M, Bury J, Mok K, McDermott CJ, Traynor BJ, Kirby J, Wharton SB, Ince PG, Hardy J, Shaw PJ. Cooper-Knock J, et al. Brain. 2012 Mar;135(Pt 3):751-64. doi: 10.1093/brain/awr365. Brain. 2012. PMID: 22366792 Free PMC article.

Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis - PubMed (original) (raw)